<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04806945</url>
  </required_header>
  <id_info>
    <org_study_id>HLX10-017-CC301</org_study_id>
    <nct_id>NCT04806945</nct_id>
  </id_info>
  <brief_title>A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 (Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) + Chemotherapy (Carboplatin/Cisplatin and Paclitaxel) vs Chemotherapy (Carboplatin/Cisplatin and Paclitaxel)in Patients With Advanced Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of HLX10(Recombinant Anti-PD-1&#xD;
      Humanized Monoclonal Antibody Injection) plus chemotherapy compared to the efficacy and&#xD;
      safety of placebo plus chemotherapy in the treatment of adult women with persistent,&#xD;
      recurrent, or metastatic cervical cancer. Chemotherapy regimens include: paclitaxel plus&#xD;
      cisplatin and paclitaxel plus carboplatin.&#xD;
&#xD;
      The primary study hypotheses are that the combination of HLX10 plus chemotherapy is superior&#xD;
      to placebo plus chemotherapy with respect to: 1) Progression-free Survival (PFS) per Response&#xD;
      Evaluation Criteria in Solid Tumors (RECIST 1.1) as assessed by the IRRC or, 2) Overall&#xD;
      Survival (OS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) (assessed by the independent radiology review committee [IRRC] based on Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)</measure>
    <time_frame>up to approximately 1 years</time_frame>
    <description>Baseline until disease progression or death, whichever occurs first</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">482</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>HLX10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLX10 + chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX10</intervention_name>
    <description>IV infusion.</description>
    <arm_group_label>HLX10</arm_group_label>
    <other_name>Recombinant humanized anti-PD-1 monoclonal antibody injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>HLX10</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>HLX10</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>HLX10</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to HLX10</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous&#xD;
             carcinoma, or adenocarcinoma of the cervix which has not been treated with systemic&#xD;
             chemotherapy and is not amenable to curative treatment (such as with surgery and/or&#xD;
             radiation)&#xD;
&#xD;
          2. CPS≥1&#xD;
&#xD;
          3. Has measurable disease per RECIST 1.1 as assessed by IRRC&#xD;
&#xD;
          4. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within&#xD;
             14 days prior to randomization&#xD;
&#xD;
          5. Has adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis.&#xD;
&#xD;
          2. Has a known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 2 years.&#xD;
&#xD;
          3. Has a history of (non-infectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis&#xD;
&#xD;
          4. Has an active infection requiring systemic therapy&#xD;
&#xD;
          5. Has a known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          6. Has received prior therapy with an anti-PD-1, anti-PD-L1 or with an agent directed to&#xD;
             another stimulatory or co-inhibitory T-cell receptor (e.g. CTLA-4）&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Cervical cancer only occurs in female.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>lingying wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>lingying wu</last_name>
    <phone>0086-010-67781331</phone>
    <email>wulingying@csco.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>lingying wu</last_name>
      <phone>008601067781331</phone>
      <email>wulingying@csco.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

